Interestingly, ORMDL3 expression showed a negative correlation with CD8+ T cell activation markers such as PRF1, GZMA, and GZMB, as well as with ISGs such as CCL5 and CXCL10 (Figure 7—figure supplement 2F), validating our finding that ORMDL3 serves as a negative regulator of the IFN signaling pathway and anti-tumor immunity. Here, PRF1 is linked to neoplasm.